Healthcare >> Analyst Interviews >> October 2, 2018
Gene Therapy Companies with Better Clinical Data and Benefits Likely to Do Well
Difei Yang, Ph.D., is Managing Director of Equity Research at Mizuho Americas, Research Division. Dr. Yang has been covering the biotech and pharma sector for nearly a decade, most recently as Managing Director at Aegis Capital. She also worked in senior equity analyst roles at Brean Capital, R.F. Lafferty, WallachBeth Capital and Auriga Global Investors. In addition, she has held senior science, program management and business development roles within the pharmaceutical industry and has authored many granted U.S. patents and peer-reviewed scientific publications. She holds a Ph.D. in chemistry from UCLA, as well as an MBA from Georgia State University and a B.S. degree in physics from Peking University, China. Profile
Word count: 2,141
TWST: Can you provide an overview of your coverage today?
Dr. Yang: I have a very broad coverage. I am looking for companies that have high